Announcement • Jun 24
Qlucore Receives EUR 0.5 Million EU Payment Qlucore has now received the third payment of approximately EUR 0.5 million under its previously awarded EU grant. The total grant amounts to EUR 2.5 million and is distributed across four installments. The project aims to accelerate the development of clinical cancer diagnostic solutions for acute myeloid leukemia (AML) and bladder cancer. Announcement • Jun 18
Qlucore AB (publ) Receives Approval for EUR 0.5 Million EU Payment Qlucore AB (publ) has received approval for a third payment of approximately EUR 0.5 million under its previously awarded EU grant. The total grant amounts to EUR 2.5 million and is distributed across four installments. The project aims to accelerate the development of clinical cancer diagnostic solutions for acute myeloid leukemia (AML) and bladder cancer. Following successful progress and review within the agreed project timeline, the next installment is now approved for disbursement. Over the course of the three-year project, Qlucore will develop and launch CE-marked software for clinical cancer diagnostics in AML and bladder cancer. The solutions are intended for use in clinical laboratories and will also support the development of companion diagnostics in collaboration with pharmaceutical partners. AML and bladder cancer are areas of particular focus due to their complex RNA profiles. These RNA-based signatures offer significant potential to improve diagnostic accuracy and treatment selection. However, such molecular information is currently not fully utilized in clinical practice. The project aims to enable broader adoption of this data to support more precise, individualized treatment decisions. Research-use-only versions of the tests for AML and bladder cancer have been available since April 2026 through Qlucore Insights. For use in clinical diagnostics, software must comply with IVDR regulations and obtain CE marking. In this project, Qlucore builds on prior investments in Qlucore Diagnostics BCP-ALL, including both software capabilities and a certified quality management system. Qlucore Diagnostics BCP-ALL 1.0 was launched in February 2025 and is currently in use at clinical laboratories. Reported Earnings • May 28
Full year 2026 earnings released: kr1.22 loss per share (vs kr5.10 loss in FY 2025) Full year 2026 results: kr1.22 loss per share. Revenue: kr21.8m (up 18% from FY 2025). Net loss: kr36.5m (loss widened 78% from FY 2025). Announcement • Oct 23
Qlucore AB (Publ) Announces Board Appointments Qlucore AB (publ) at its annual general meeting held on October 23, 2025, approved in accordance with the Nomination Committee's proposal, Lars Pålsson (Chairman), Carl Palmstierna and Kjell Sjöström were elected as members of the Board of Directors. Announcement • Sep 24
Qlucore AB (publ), Annual General Meeting, Oct 23, 2025 Qlucore AB (publ), Annual General Meeting, Oct 23, 2025, at 11:00 W. Europe Standard Time. Location: at the companys office in lund, lund Sweden New Risk • Nov 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (€1.89m market cap, or US$2.07m). Minor Risk Revenue is less than US$5m (kr31m revenue, or US$2.9m). New Risk • Sep 06
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -kr39m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr39m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 32% per year over the past 5 years. Market cap is less than US$10m (€2.59m market cap, or US$2.87m). Minor Risk Revenue is less than US$5m (kr37m revenue, or US$3.6m). Reported Earnings • Aug 30
First quarter 2025 earnings released: kr1.87 loss per share (vs kr1.24 loss in 1Q 2024) First quarter 2025 results: kr1.87 loss per share (further deteriorated from kr1.24 loss in 1Q 2024). Revenue: kr5.06m (down 48% from 1Q 2024). Net loss: kr7.53m (loss widened 51% from 1Q 2024). Announcement • Aug 28
Qlucore AB (publ) to Report Q1, 2025 Results on Aug 29, 2024 Qlucore AB (publ) announced that they will report Q1, 2025 results on Aug 29, 2024 New Risk • Jun 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr39m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 32% per year over the past 5 years. Market cap is less than US$10m (€2.97m market cap, or US$3.24m). Minor Risk Revenue is less than US$5m (kr40m revenue, or US$3.8m). Reported Earnings • Jun 04
Full year 2024 earnings released: kr3.89 loss per share (vs kr3.96 loss in FY 2023) Full year 2024 results: kr3.89 loss per share (improved from kr3.96 loss in FY 2023). Revenue: kr39.5m (up 26% from FY 2023). Net loss: kr15.7m (loss narrowed 1.6% from FY 2023). Announcement • May 28
Qlucore Starts Project After Receiving EU Grant to Advance Personalized Cancer Treatment Qlucore has passed the evaluation phase and will receive a prestigious EIC Accelerator grant of EUR 2.5 million to accelerate the development of clinical cancer diagnostics solutions for acute myeloid leukemia (AML) as well as bladder cancer. In March the grant was made public and Qlucore is now starting the project and has received the first payment. During the project Qlucore will develop and launch CE-marked software for clinical cancer diagnostics for the two cancer types. The project will stretch over three years, with objectives to develop solutions for use by clinical laboratories as well as companion diagnostics (CDx) solutions in collaboration with pharma companies. The selected cancer disease areas are especially suited to the solutions as both cancer types have multiple changes on RNA level that can be utilized to improve diagnosis and treatment. Currently this information is not fully used to provide the right therapy for the right patient. The aim of the project is to change this. Reported Earnings • Mar 01
Third quarter 2024 earnings released: kr0.69 loss per share (vs kr0.72 loss in 3Q 2023) Third quarter 2024 results: kr0.69 loss per share (improved from kr0.72 loss in 3Q 2023). Revenue: kr10.9m (up 17% from 3Q 2023). Net loss: kr2.76m (loss narrowed 4.9% from 3Q 2023). Announcement • Feb 01
Qlucore Diagnostics for Pediatric Leukemia Takes A Significant Step Closer to Ce Marking Qlucore has taken the final major step in the process towards a CE-marked medical device for in-vitro diagnostics by submitting the technical documentation to a Notified Body. The CE marked product, Qlucore Diagnostics, is due to be launched in February 2025. The targeted cancer disease is acute lymphoblastic leukemia (ALL) in children, a condition where mortality and treatment-related complications remain high. In order for a medical device to be used in healthcare diagnostics, IVDR regulations require the device to have CE marking. The performance study initiated by Qlucore in December 2023 is now complete, with expected positive results. The technical documentation can now be reviewed and approved by the Notified Body. Qlucore has contracted BSI (British Standards Institute) as the Notified Body, and the Institute will conduct a formal review of the product's safety and performance. The result is regulatory approval and CE marking, and the estimated timeframe for regulatory approval of Qlucore Diagnostics BCP-ALL is February 2025. The intended use of the software is to qualitatively analyze the genetic changes that may cause the disease condition BCP-ALL. This is done based on gene activity levels and the identification of gene fusions. The classification into genetic subgroups is performed using a machine learning-based classifier and subsequently, a probability is presented that indicates the likelihood that the patient belongs to one of six defined subgroups. Announcement • Dec 14
Qlucore Announces Swedish Innovation Evaluated for Clinical Diagnosis of Pediatric Leukemia Qlucore has taken a significant and crucial step towards obtaining a CE marked solution, initiating a formal performance evaluation study in Sweden and Denmark. Results from the study are expected early in 2024. The specific cancer to be tested in the study is acute lymphoblastic leukemia (BCP-ALL) in children. Leukemia in children, i.e. BCP-ALL continues to have high mortality rates an treatment-related complications. IVDR regulations for medical devices require products to be CE marked prior to use in healthcare diagnostics. Once the ongoing performance evaluation study is completed, Qlucore will be required to compile a study report and create a technical file that will be submitted to a Notified Body. BSI (British Standards Institute) has been contracted as the Notified Body, and they will conduct the formal review regarding the product's safety and performance. The estimated timeframe for regulatory approval and CE marking of Qlucore Diagnostics BCP-ALL is February 2025. Reported Earnings • Nov 30
Second quarter 2024 earnings released: kr0.81 loss per share (vs kr1.03 loss in 2Q 2023) Second quarter 2024 results: kr0.81 loss per share (improved from kr1.03 loss in 2Q 2023). Revenue: kr10.4m (up 52% from 2Q 2023). Net loss: kr3.26m (loss narrowed 22% from 2Q 2023). Announcement • Nov 29
Qlucore AB (publ), Annual General Meeting, Sep 09, 2024 Qlucore AB (publ), Annual General Meeting, Sep 09, 2024. Board Change • Oct 30
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Lars Hockenstrom was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Board Change • Sep 14
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 1 was an independent director. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Director Helle Fisker was the last independent director to join the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Announcement • Sep 08
Qlucore AB (Publ) Appoints Lars Höckenström as A Member of the Board of Directors Qlucore AB (publ) appointed Lars Höckenström as a member of the Board of Directors at its annual general meeting held on September 7, 2023. Reported Earnings • Sep 01
First quarter 2024 earnings released: kr1.24 loss per share (vs kr1.20 loss in 1Q 2023) First quarter 2024 results: kr1.24 loss per share (further deteriorated from kr1.20 loss in 1Q 2023). Revenue: kr10.8m (up 94% from 1Q 2023). Net loss: kr5.00m (loss widened 3.5% from 1Q 2023). New Risk • Aug 18
New major risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (€3.38m market cap, or US$3.67m). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Revenue is less than US$5m (kr31m revenue, or US$2.9m). New Risk • Jul 07
New major risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 9.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 45% per year over the past 5 years. Market cap is less than US$10m (€2.98m market cap, or US$3.23m). Minor Risks Share price has been volatile over the past 3 months (9.8% average weekly change). Revenue is less than US$5m (kr31m revenue, or US$2.9m). Reported Earnings • Jun 02
Full year 2023 earnings released: kr3.96 loss per share (vs kr2.90 loss in FY 2022) Full year 2023 results: kr3.96 loss per share (further deteriorated from kr2.90 loss in FY 2022). Revenue: kr36.4m (up 62% from FY 2022). Net loss: kr15.9m (loss widened 37% from FY 2022). Reported Earnings • Mar 05
Third quarter 2023 earnings released: kr0.72 loss per share (vs kr0.10 profit in 3Q 2022) Third quarter 2023 results: kr0.72 loss per share (down from kr0.10 profit in 3Q 2022). Revenue: kr10.6m (up 48% from 3Q 2022). Net loss: kr2.90m (down kr3.31m from profit in 3Q 2022). Reported Earnings • Nov 30
Second quarter 2023 earnings released: kr1.03 loss per share (vs kr1.62 loss in 2Q 2022) Second quarter 2023 results: kr1.03 loss per share (improved from kr1.62 loss in 2Q 2022). Revenue: kr7.96m (up 53% from 2Q 2022). Net loss: kr4.15m (loss narrowed 2.9% from 2Q 2022). Announcement • Nov 25
Qlucore AB (publ) to Report First Half, 2023 Results on Nov 28, 2022 Qlucore AB (publ) announced that they will report first half, 2023 results on Nov 28, 2022 Announcement • Nov 18
Qlucore Software Used in New Project to Prevent Cardiovascular Diseases Qlucore software used in new project to prevent cardiovascular diseases. Receives SEK 1.5 million to provide patients with better treatment, will play an important role as one of five key partners in the OmegaPerMed project. The project aims to optimize treatment with omega-3 to prevent cardiovascular diseases (CVD). Cardiovascular diseases, such as heart attack, stroke and angina, are the most common causes of death in populations, and therefore prevention is vital. In clinical trials, the project will try to detect interactions between genes, exposure to polyunsaturated fatty acid (PUFA), CVD risk and lipidomic markers against beneficial CVD effects of omega-3 PUFA. I This means that if successful, patients can be divided into subgroups in order to receive a more individualized treatment. Announcement • Sep 27
Qlucore Receives Patent in Europe Qlucore, whose software creates the conditions for faster, more precise, better cancer diagnostics and helps researchers with data analysis, has received a patent in Europe. This is for a new feature which generates robust analysisanswers, even in the presence of large data sets and information overload. The new function is applicable to many application areas. Analysis of large data sets often results in extensive lists of variables, which may, for example, represent genes associated with some outcome of biomedical interest. A biological interpretation is often complicated by the statistical instability of the lists employed. Qlucore's solution means that the amount of information is condensed, improving the basis for analysis. The new solution introduces a measure of statistical exchangeability for the variables which can partially capture, for example, biological redundancy. It enables more stable analyses.The function is developed using a so-called `statistical exchangeability' concept, which means that the invention measures the redundancy or excess information found in the data using an algorithm. This gives the user more stable conditions for comparing lists, which can, for example, mean that researchers or doctors can determine with greater certainty whether a patient will respond to a certain treatment or not. Qlucore's new patented function can result in ordered lists of important biological information that are more stable and resistant to small changes in the underlying data than existing methods. The invention and patent is a significant piece of the puzzle in high-dimensional data analysis that requires robust answers. Reported Earnings • Sep 02
First quarter 2023 earnings released First quarter 2023 results: Revenue: kr6.97m (up 173% from 1Q 2022). Net loss: kr4.83m (loss widened 19% from 1Q 2022). Announcement • Aug 27
Qlucore Expands Its Leukemia Diagnostics Solution Qlucore expanding its collaboration in precision diagnostics with Lund University with the aim of developing solutions for improved diagnostics of more forms of blood cancer. Combining the software expertise of Qlucore with the cancer diagnostics expertise of Lund University, the collaboration aims to develop and evaluate so-called classification models for improved diagnostics of two different forms of blood cancer, acute lymphoblastic and acute myeloid leukemia. The classification models are then used together with the AI-based products Qlucore Diagnostics and Qlucore Insights. The goal is to support more customized cancer treatment and to obtain CE marking for Qlucore Diagnostics. Precision diagnostics for cancer has developed rapidly in recent years, driven by so-called next generation sequencing (NGS). Until now, the focus has been on mutations and variants in the genetic code at the DNA level, which have been used for both patient classification and cancer treatment decisions. For some time now, interest has increased in techniques based on measurements of gene activity levels as this provides improved opportunities to determine which diagnosis a patient receives, and which treatment is most appropriate. Announcement • Aug 26
Qlucore Ab (Publ) to Report Q1, 2023 Results on Aug 30, 2022 Qlucore Ab (Publ) announced that they will report Q1, 2023 results on Aug 30, 2022 Reported Earnings • Jun 12
Full year 2022 earnings released Full year 2022 results: Revenue: kr26.0m (up 54% from FY 2021). Net loss: kr11.7m (loss widened 93% from FY 2021). Announcement • Apr 08
Qlucore Names Erik Söderbäck as Head of Diagnostics Sales Qlucore Ab (Publ) employed Erik Söderbäck as head of diagnostics sales. Erik Söderbäck has over 30 years of experience in DNA sequencing and most recently came from QIAGEN Europe, where he was responsible for marketdevelopment of products and solutions for clinical genomics. He will join the team April 7th. Reported Earnings • Mar 06
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: kr0.10. Revenue: kr7.15m (flat on 3Q 2021). Net income: kr410.0k (up kr410.0k from 3Q 2021). Profit margin: 5.7% (up from null in 3Q 2021). Revenue was in line with analyst estimates. Announcement • Feb 17
Qlucore AB (Publ) Appoints Helle Fisker as Regular Member of the Board Qlucore AB (publ) announced that on 16 February 2022 an Extraordinary General Meeting, resolved, for the period until the end of the next Annual General Meeting, that Helle Fisker is newly appointed as regular member of the Board. Announcement • Feb 08
Qlucore Appoints Ulf Ahlfors as Head of R&D Qlucore has appointed Ulf Ahlfors as Head of R&D. Ahlfors joins Qlucore from Assa Abloy where he was product manager. He joins Qlucore on February 7th, 2022. He was also part of the growth company Sinch from its foundation. Announcement • Feb 02
Qlucore Announces Management Changes Qlucore announced that it has appointed Cecilia Grotte with the intention to install her as CFO to take over from interim CFO Anders Bergstrand. Cecilia Grotte's previous employment was as CFO at SimFAS Sweden. Her employment with Qlucore begins on 1st February when she will join the Company's management team. Cecilia Grotte has long and extensive experience in the bank/finance sectors as well asthe pharmaceutical sector, with more than ten years as CFO for Nordic Drugs. Announcement • Dec 16
Qlucore AB (publ) Announces Major New Release for Bioinformatics Qlucore AB (publ) announced Qlucore Omics Explorer (QOE) version 3.8, with new features that will improve ease of use and enhance performance. Qlucore Omics Explorer is a next-generation bioinformatics software for research in life science, plant- and biotech industries, as well as academia. The powerful and flexible visualization-based data analysis tool with inbuilt powerful statistics delivers immediate results and provides instant exploration and visualization of big data. Finally, V3.8 offers improved window handling and support for new operating system versions including Mac OS 12 and Windows 11. 
